Cerebrolysin
Cerebrolysin (porcine brain-derived peptide preparation)
Also known as: FPF 1070, CERE, Renacenz
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
A porcine brain-derived peptide preparation approved in 40+ countries for stroke recovery and cognitive disorders. Contains a mix of neurotrophic factors mimicking BDNF, NGF, and GDNF activity.
Quick Facts
Approved for clinical use in over 40 countries including Austria, Germany, Russia, China, South Korea, and other European and Asian nations. Not FDA-approved in the United States. Manufactured by EVER Neuro Pharma (formerly Ebewe Pharma), Austria.
Overview
Cerebrolysin is a porcine (pig) brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of purified pig brain proteins. It is not a single peptide but a complex, standardized mixture designed to mimic the action of endogenous neurotrophic factors.
Developed in Austria and used clinically since the 1970s, Cerebrolysin is one of the most extensively studied neuropeptide preparations in the world, with clinical use spanning stroke recovery, traumatic brain injury, Alzheimer's disease, and other neurodegenerative conditions. It has been the subject of over 200 clinical studies.
Cerebrolysin's unique composition includes peptide fragments that functionally resemble BDNF (brain-derived neurotrophic factor), GDNF (glial cell line-derived neurotrophic factor), NGF (nerve growth factor), and CNTF (ciliary neurotrophic factor). This multi-target neurotrophic profile is central to its therapeutic rationale — rather than targeting a single pathway, it provides broad neurotrophic support.
Mechanism of Action
Cerebrolysin acts as a multimodal neurotrophic agent through several parallel mechanisms. Its peptide components activate neurotrophic factor signaling pathways, particularly the PI3K/Akt and MAPK/ERK cascades, which promote neuronal survival, synaptic plasticity, and neurogenesis.
It enhances synaptic function by increasing the expression of synaptic proteins including synaptophysin and GAP-43 (growth-associated protein-43), which are critical for synaptic transmission and axonal growth. Studies demonstrate increased dendritic branching and spine density in treated neurons.
Cerebrolysin exerts neuroprotective effects by reducing excitotoxicity (glutamate-mediated neuronal death), inhibiting calpain activation (a protease involved in neuronal degeneration), and scavenging free radicals. It modulates GSK-3β (glycogen synthase kinase-3 beta) activity, which is directly relevant to tau phosphorylation and Alzheimer's pathology.
It promotes neurogenesis in the adult brain by increasing proliferation and differentiation of neural progenitor cells in the hippocampal dentate gyrus and subventricular zone. It also supports oligodendrogenesis, contributing to remyelination processes after demyelinating injuries.
Importantly, Cerebrolysin's peptide components are small enough to cross the blood-brain barrier, unlike full-length neurotrophic proteins (BDNF, NGF) which cannot.
Research Summary
Cerebrolysin has one of the largest clinical evidence bases of any neuropeptide therapy, though the quality and rigor of studies varies significantly.
Stroke research represents the most developed area. The CASTA (Cerebrolysin Acute STroke study in Asia) trial, a large multicenter RCT, evaluated Cerebrolysin in acute ischemic stroke patients. While the primary endpoint (improvement on the ARAT scale at 90 days) narrowly missed statistical significance, subgroup analyses and secondary endpoints showed benefits in patients with moderate-to-severe stroke. The CERE-STAT trials and subsequent studies have continued to explore stroke applications.
Alzheimer's disease research includes multiple randomized controlled trials. A Cochrane review analyzed the evidence and found some positive signals for cognitive outcomes, though noted methodological limitations. The largest trial (Cerebrolysin vs. donepezil) showed comparable cognitive improvements. E-ADEPT and other trials demonstrated stabilization or improvement on ADAS-cog scores.
Traumatic brain injury studies show improvements in cognitive recovery and functional outcomes, with the CAPTAIN trial (Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery) providing supportive data.
Key limitations include: (1) Many studies originated from regions with less rigorous regulatory standards. (2) The Cochrane review called for larger, better-designed confirmatory trials. (3) The FDA has not approved Cerebrolysin, reflecting its assessment that the evidence does not yet meet US regulatory standards. (4) As a biological product, batch-to-batch variability is a theoretical concern, though manufacturing is standardized.
Key References
Cerebrolysin in acute ischemic stroke: a randomized, placebo-controlled, phase III, multicenter trial (CASTA)
Heiss WD, Brainin M, Bornstein NM, et al. · Stroke (2012) · 10.1161/STROKEAHA.111.649806
Large multicenter RCT of Cerebrolysin in acute ischemic stroke. Primary endpoint narrowly missed significance, but subgroup analyses showed benefit in moderate-to-severe strokes.
Cerebrolysin for vascular dementia
Chen N, Yang M, Guo J, Zhou M, Zhu C, He L · Cochrane Database of Systematic Reviews (2013) · 10.1002/14651858.CD008900.pub2
Cochrane systematic review evaluating Cerebrolysin for vascular dementia. Found some evidence of cognitive benefit but called for larger and more rigorous confirmatory trials.
A randomized, double-blind, placebo-controlled trial of Cerebrolysin in patients with acute ischemic stroke (CERE-STAT)
Bornstein NM, Guekht A, Vester J, et al. · Journal of Stroke and Cerebrovascular Diseases (2018) · 10.1016/j.jstrokecerebrovasdis.2017.12.015
Follow-up RCT to CASTA with refined patient selection. Demonstrated improvements in early neurological recovery and functional outcomes in ischemic stroke patients.
Neurotrophic and neuroprotective effects of Cerebrolysin
Allegri RF, Guekht A · Drugs of Today (2012) · 10.1358/dot.2012.48.S.1739721
Review of Cerebrolysin's mechanisms of action including neurotrophic signaling, synaptic plasticity enhancement, neuroprotection, and neurogenesis promotion.
Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a six-month open-label extension
Alvarez XA, Cacabelos R, Laredo M, et al. · European Journal of Neurology (2006) · 10.1111/j.1468-1331.2006.01166.x
RCT showing Cerebrolysin improved cognitive function (ADAS-cog scores) in Alzheimer's patients over 24 weeks, with sustained benefits during the open-label extension.
Protocols
Cognitive enhancement / neuroprotection (clinical)
Standard clinical protocol used in approved countries. IM injections limited to 5 mL per site; higher volumes require multiple injection sites or IV administration.
Stroke / acute neurological injury (clinical)
Based on CASTA and CERE-STAT trial protocols. IV administration required for doses above 10 mL. Infusion over 15–60 minutes. Always initiated under medical supervision in a clinical setting.
Alzheimer's disease (clinical)
Based on clinical trial protocols. Some studies used 10 mL IM daily as an alternative. Treatment courses are typically repeated, as cognitive benefits may wane after discontinuation.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Injection site pain or irritation Local pain, redness, or swelling at the IM injection site. More common with larger volumes. |
| uncommon | Dizziness Reported during or shortly after IV infusion. Usually transient. |
| uncommon | Headache Mild headache reported in clinical trials, generally self-limiting. |
| uncommon | Nausea GI discomfort occasionally reported, more common with higher doses. |
| rare | Agitation or insomnia Rare reports of psychomotor agitation, particularly with evening dosing. Recommend morning administration. |
| rare | Allergic reaction As a porcine-derived biological product, allergic reactions are possible. Contraindicated in patients with known pork allergy. |
Contraindications
- —Known allergy to porcine (pig) products
- —Epilepsy or history of seizure disorder (may lower seizure threshold in rare cases)
- —Severe renal impairment (limited excretion data)
- —Pregnancy or breastfeeding (insufficient safety data)
- —Status epilepticus
Interactions
- —MAO inhibitors — theoretical risk of enhanced monoamine signaling; concurrent use not recommended
- —Antidepressants (SSRIs, SNRIs) — Cerebrolysin affects serotonergic and noradrenergic systems; monitor for serotonin syndrome
- —Antiepileptic drugs — Cerebrolysin may theoretically affect seizure threshold; dose adjustment may be needed
- —Lithium — potential for additive neurotrophic effects; monitor lithium levels
Reconstitution & Storage
Related Peptides
Cerebrolysin provides broad neurotrophic support through its multi-peptide composition, complementing the more targeted mechanisms of Semax (BDNF modulation, melanocortin pathway) and Selank (anxiolytic, immune modulation). Dihexa targets the HGF/c-Met pathway for synaptic formation. These compounds address overlapping but distinct aspects of cognitive enhancement and neuroprotection.